Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies
Abstract The urgent need for a treatment of COVID-19 has left researchers with limited choice of either developing an effective vaccine or identifying approved/investigational drugs developed for other medical conditions for potential repurposing, thus bypassing long clinical trials. In this work, w...
Enregistré dans:
Auteurs principaux: | Puneet Rawat, Divya Sharma, Ambuj Srivastava, Vani Janakiraman, M. Michael Gromiha |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/91d1b92f687040aebb2d043b3dfc7e60 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Exploring the sequence features determining amyloidosis in human antibody light chains
par: Puneet Rawat, et autres
Publié: (2021) -
A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
par: Syed Mohammed Basheeruddin Asdaq, et autres
Publié: (2021) -
The Road to Toxin-Targeted Therapeutic Antibodies
par: Thomas R. Kozel
Publié: (2014) -
Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
par: Jean-Nicolas Tournier, et autres
Publié: (2019) -
Antibody or Anybody? Considering the Role of MRGPRX2 in Acute Drug-Induced Anaphylaxis and as a Therapeutic Target
par: Graham A. Mackay, et autres
Publié: (2021)